Understanding the regulatory pathway for drug development can feel overwhelming, especially when navigating the relationship between IND and NDA applications. These two critical submissions represent different phases of bringing a new drug to market, each serving distinct purposes in the regulatory timeline.
The sequence of filing an IND before an NDA is fundamental to drug development, but knowing when to file each application and what comes between them requires careful planning and regulatory expertise.
What is the difference between IND and NDA?
An IND (Investigational New Drug) application allows clinical testing of an experimental drug in humans, while an NDA (New Drug Application) requests FDA approval to market the drug commercially. The IND focuses on safety data and study protocols, whereas the NDA provides comprehensive evidence of safety and efficacy.
The IND application primarily contains preclinical data, manufacturing information, and clinical trial protocols. It demonstrates that the drug is reasonably safe for initial human testing and that the proposed studies are scientifically sound. Companies must wait 30 days after IND submission before beginning clinical trials, unless the FDA places the application on clinical hold.
In contrast, the NDA represents the culmination of years of clinical research. This comprehensive document includes all data from preclinical studies through Phase III trials, detailed manufacturing information, proposed labeling, and risk assessment plans. The NDA must prove that the drug’s benefits outweigh its risks for the intended patient population.
When do you file an IND application?
You file an IND application before conducting any clinical trials in humans, typically after completing preclinical studies that demonstrate reasonable safety. The IND must be submitted at least 30 days before the first human dose, allowing the FDA to review your proposed clinical trial.
The timing depends on several key milestones in drug development. First, you need adequate preclinical safety data from animal studies, including toxicology and pharmacokinetic information. Second, you must have sufficient drug substance and drug product available for clinical testing, manufactured under appropriate quality standards.
Additionally, your clinical protocol must be finalized, including the study design, patient population, dosing regimen, and safety monitoring plans. Institutional Review Board approval and clinical site preparation should also be underway, as these elements support the IND submission and enable rapid study initiation once FDA clearance is obtained.
What comes after IND approval in drug development?
After IND approval, you proceed through three phases of clinical trials: Phase I (safety and dosing), Phase II (efficacy signals and optimal dosing), and Phase III (definitive efficacy and safety). Each phase builds on previous data and may require protocol amendments or a new IND submission for significant changes.
Phase I trials typically involve 20-100 healthy volunteers or patients, focusing on determining safe dosage ranges and identifying side effects. These studies establish the maximum tolerated dose and provide initial pharmacokinetic data. Phase I usually lasts several months to a year.
Phase II trials expand to 100-300 participants and evaluate whether the drug works for specific conditions while continuing to monitor safety. These studies often include dose-ranging components to identify the optimal therapeutic dose. Phase II can last from several months to two years.
Phase III trials involve 300-3,000 participants across multiple sites, comparing the new drug with existing standard treatments or a placebo. These pivotal studies provide the primary evidence of efficacy and the comprehensive safety data required for NDA submission. Phase III typically takes one to four years to complete.
How do you know when you’re ready to file an NDA?
You’re ready to file an NDA when you have completed adequate and well-controlled clinical trials demonstrating safety and efficacy, established commercial-scale manufacturing processes, and compiled comprehensive data supporting the proposed indication and labeling. Successful Phase III trials are typically the primary trigger for NDA submission.
Several key criteria indicate NDA readiness. Your pivotal clinical trials must meet their primary endpoints with statistical significance, showing that the drug is effective for its intended use. The overall safety profile should be acceptable, with a favorable benefit-risk ratio supported by adequate exposure data across the target patient population.
Manufacturing readiness is equally critical. You need validated commercial-scale production processes, stability data supporting the proposed shelf life, and quality control methods that ensure consistent product quality. Regulatory compliance includes ensuring that all clinical sites and manufacturing facilities are ready for potential FDA inspections.
Additional considerations include completing required pediatric studies or obtaining waivers, addressing any FDA feedback from pre-NDA meetings, and ensuring your proposed labeling accurately reflects the clinical data. Risk evaluation and mitigation strategies may also be necessary for certain drug classes.
What happens during NDA review and approval?
During NDA review, the FDA conducts a comprehensive evaluation lasting 6-12 months, examining all clinical data, manufacturing information, and proposed labeling. The review includes scientific assessment, facility inspections, and potentially an advisory committee meeting before making an approval decision.
The FDA review process follows a structured timeline. Within 60 days of submission, the agency determines whether to file the NDA for review or issue a refuse-to-file letter for incomplete applications. Once filed, the standard review period is 10 months, though priority review applications receive a 6-month timeline.
During review, FDA scientists evaluate clinical trial data, assess manufacturing quality and controls, and review proposed labeling. The agency may request additional information or clarification through information requests. Facility inspections of clinical sites and manufacturing locations typically occur during the review period.
For certain applications, the FDA convenes an advisory committee meeting where external experts publicly discuss the drug’s benefits and risks. While advisory committee recommendations are non-binding, they significantly influence FDA decision-making. The review concludes with either approval, a complete response letter requesting additional information, or a denial.
How Starodub helps with clinical trial applications
We provide comprehensive support for both IND and NDA submissions, guiding biopharmaceutical companies through every step of the regulatory pathway. Our experienced team understands the critical timing and requirements for successful clinical trial applications, ensuring your submissions meet both scientific and regulatory standards.
Our regulatory services include:
- IND preparation and submission strategy development
- Clinical protocol review and regulatory compliance assessment
- NDA compilation and submission management
- FDA meeting preparation and regulatory communication
- Post-submission support during agency review periods
With over 400 completed projects supporting more than 300 clients, we bring proven expertise to streamline your regulatory submissions and accelerate your path to market approval. Contact us to discuss how we can support your clinical trial application strategy and ensure regulatory success.
